bullish
China Population Policies Impact on Healthcare Companies Series - Part 1
897 Views18 Jul 2023 08:21
SUMMARY
- China has started taking measures to optimize fertility policies. The inclusion of assisted reproduction technologies in medical insurance is a general trend, which would generate increasing demand in the future.
- From the current domestic assisted reproductive industry chain, there is significant import substitution space and growth potential in the fields of related drugs, prenatal/newborn genetic testing, and downstream medical services.
- Companies such as Livzon/BGI/Jinxin would be the direct beneficiaries of related policy. We analyzed the industry characteristics, investment rationale, key risks and comparison with peers of these companies.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Population Policies Impact on Healthcare Companies Series – Part 419 Apr 2024
- China Population Policies Impact on Healthcare Companies Series - Part 305 Jan 2024
- China Population Policies Impact on Healthcare Companies Series – Part 203 Oct 2023
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
- Pre-IPO InSilico Medicine - AI Pharmaceutical Is Immature; Valuation Expansion Relies on Imagination13 Jul 2023
- BeiGene (6160.HK/BGNE.US) - Novartis Chose to Escape Before Tragedy of TIGIT Truly Comes12 Jul 2023
- Moderna Inc (MRNA US) - What Would Happen After Moderna Enters China?12 Jul 2023
x